Theratechnologies Inc
TSX:TH
Theratechnologies Inc
TSX:TH
Price:
1.66 CAD
Market Closed
Updated:
May 14, 2024
Theratechnologies Inc
Cost of Revenue
|
Theratechnologies Inc
Cost of Revenue Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Theratechnologies Inc
TSX:TH
|
Cost of Revenue
-$20.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-16%
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cost of Revenue
-$21.5m
|
CAGR 3-Years
-655%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-115%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cost of Revenue
-CA$936k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-1%
|
See Also
What is Theratechnologies Inc's Cost of Revenue?
Cost of Revenue
-20.2m
USD
-20.2m
USD
Based on the financial report for Feb 29, 2024, Theratechnologies Inc's Cost of Revenue amounts to -20.2m USD.
What is Theratechnologies Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-16%
-16%
Over the last year, the Cost of Revenue growth was 19%. The average annual Cost of Revenue growth rates for Theratechnologies Inc have been 9% over the past three years , -3% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet
